Literature DB >> 8322782

Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy.

H H Parving1, U M Smidt, E Hommel, E R Mathiesen, P Rossing, F Nielsen, M A Gall.   

Abstract

The effect of long-term, aggressive, antihypertensive treatment on kidney function in diabetic nephropathy was studied prospectively in 11 insulin-dependent diabetic patients (mean age, 30 years). Renal function was assessed every 4 months by measurement of glomerular filtration rate (GFR) (single-bolus 51Cr-EDTA technique) and by albuminuria (radial immunodiffusion). During the median pretreatment period of 2.4 years (range, 1.9 to 5.5 years), the GFR decreased significantly and albuminuria and the arterial blood pressure increased significantly. During the 9.7-year (range, 2.8 to 10.4 year) period of antihypertensive treatment with metoprolol, hydralazine, and furosemide, the arterial blood pressure decreased from 143/96 mm Hg to 130/84 mm Hg and albuminuria decreased from 1,038 micrograms/min to 547 micrograms/min. The rate of decline in GFR decreased from 10.7 mL/min/yr (range, 5.3 to 17.5 mL/min/yr) before treatment to 2.5 mL/min/yr (range, 0.5 to 4.8 mL/min/yr) during treatment. The rate of decline in GFR is significantly smaller during the last 6 years compared with the first 3 years in patients who received long-term antihypertensive treatment (> or = 9 years). One patient died from acute myocardial infarction (GFR, 46 mL/min/1.73 m2). Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8322782     DOI: 10.1016/s0272-6386(12)70185-3

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  19 in total

Review 1.  Management of diabetic nephropathy.

Authors:  L Foggensteiner; S Mulroy; J Firth
Journal:  J R Soc Med       Date:  2001-05       Impact factor: 5.344

2.  Green tea (Camellia sinensis) attenuates nephropathy by downregulating Nox4 NADPH oxidase in diabetic spontaneously hypertensive rats.

Authors:  Pérola D B Ribaldo; Denise S Souza; Subrata K Biswas; Karen Block; Jacqueline M Lopes de Faria; José B Lopes de Faria
Journal:  J Nutr       Date:  2008-12-03       Impact factor: 4.798

Review 3.  The calcium channel blocker controversy in patients with diabetic nephropathy: Is there an issue?

Authors:  L M Ruilope; C Campo; J Segura
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

Review 4.  Nephropathy in youth and young adults with type 2 diabetes.

Authors:  Carolina Solis-Herrera; Curtis L Triplitt; Jane L Lynch
Journal:  Curr Diab Rep       Date:  2014-02       Impact factor: 4.810

Review 5.  New potential agents in treating diabetic kidney disease: the fourth act.

Authors:  Mark E Williams
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 6.  Antihypertensive drugs and diabetic nephropathy.

Authors:  P S Mehler; R W Schrier
Journal:  Curr Hypertens Rep       Date:  1999 Apr-May       Impact factor: 5.369

Review 7.  Antihypertensive drugs and the kidney.

Authors:  Mitra K Nadim; Renee Dua; Vito M Campese
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

Review 8.  Blood pressure control--effects on diabetic nephropathy progression: how low does blood pressure have to be?

Authors:  Christopher A Newton; Philip Raskin
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

9.  Prolonged administration enhances the renoprotective effect of pentoxifylline via anti-inflammatory activity in streptozotocin-induced diabetic nephropathy.

Authors:  Kum Hyun Han; Sang Youb Han; Han Seong Kim; Young Sun Kang; Dae Ryong Cha
Journal:  Inflammation       Date:  2010-06       Impact factor: 4.092

Review 10.  The role of sulodexide in the treatment of diabetic nephropathy.

Authors:  Ram Weiss; Robert Niecestro; Itamar Raz
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.